Immunoassay Market Report Scope & Overview:

The Global Immunoassay Market was valued at USD 34.70 Billion in 2025 and is projected to reach USD 56.35 Billion by 2035, expanding at a CAGR of 4.97% during the forecast period 2026–2035.

The global immunoassay market is steadily growing because of a rise in the incidences of infectious diseases, cancer, endocrine, chronic, cardiovascular and autoimmune diseases where urgent and highly sensitive diagnostic methods are required to treat them in time. Immunoassays continue to remain as the largest in vitro diagnostic technology due to their good analytical sensitivity, specificity, the ease with which they can be automated, and the ability to analyze high volumes of tests at one go. Increasing focus on early diagnosis, screening and diagnostic programs, routine clinical testing and personalized medicine are driving the demand among hospitals, reference laboratories, diagnostic centers.

Along with increasing investment on the expansion of laboratory testing infrastructure and rising health expenditure leading to increased commercial opportunities in both developed and emerging healthcare markets. Technological development is altering new immunoassay platforms through automation, AI-based laboratory workflow processes, multiplexing test capacities, digital lab management and cloud-based connectivity among diagnostics, due to which companies are heavily investing on high throughput chemiluminescence analyzers, next generation fluorescent immunoassay machines, automated sample handlers and software-based quality management systems to better laboratory efficiency and clinical accuracy.

Market Size and Forecast:                                                                          

• Market Size 2026E: USD 36.42 Billion

• Market Size 2035: USD 56.35 Billion

• CAGR: 4.97% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On Immunoassay Market - Request Free Sample Report

Immunoassay Market Trends:

• Growing adoption of automated chemiluminescence immunoassay diagnostic platforms.

• Rising biomarker-based diagnostics supporting precision medicine initiatives globally.

• Increasing laboratory digitalization using AI-enabled workflow automation solutions.

• Expansion of multiplex immunoassay testing across clinical laboratories worldwide.

• Growing demand for decentralized rapid immunodiagnostic testing technologies.

U.S. Immunoassay Market Size Outlook:    

The U.S. Immunoassay Market was valued at USD 12.13 billion in 2025 and is expected to reach approximately USD 18.14 billion by 2035, expanding at a CAGR of 4.11% during 2026–2035.

The United States has the largest market share for NA immunoassay market based on higher adoption of automatic instruments, comprehensive clinic test, comprehensive diagnostic infrastructure, and higher business operation of worldwide diagnosis manufacturer The major factors drive such growth includes greater prevalence of chronic diseases, expansion of cancer scanning programs, widespread Infectious diseases investigation, increased use of BI marker supported diagnose devices, Large amount of spending by hospitals and individual labs with automation on immunoassay analyzer, lab information systems, integrate platform to upgrade lab operation and enhance their throughput for hospital system.

Moreover, ongoing developments in chemistry on immunoassay and development of integrated digital pathology/AI for optimize labor system and increase multibiomarker test also enhance its dominancy in NA market. Pharmacovigilance department are investing in immune-assays, as does governments are involved with public test infrastructure of nationwide through Public Health Plan etc. The US-based major diagnostic vendors expand their large throughput immunoassay test solutions targeting on the oncology care, cardiac biomarker, Infectious and women’s Health areas throughout 2025-2026 and significantly increased the investment in integrate diagnostic workplace which supports fully automatic lab on systems AI enable process.

Immunoassay Market Segment Analysis:

• By Product, reagents & kits dominated the market with 63.00% share in 2025, while software & services is projected to witness the fastest growth with 7.46% CAGR during the forecast period 2026–2035.

• By Technology, chemiluminescence immunoassay dominated the market with 34.00% share in 2025, while fluorescence immunoassay is projected to witness the fastest growth with 6.21% CAGR during the forecast period 2026–2035.

• By Application, infectious diseases dominated the market with 28.00% share in 2025, while oncology is projected to witness the fastest growth with 6.90% CAGR during the forecast period 2026–2035.

• By End User, hospitals & diagnostic laboratories dominated the market with 48.00% share in 2025, while pharmaceutical & biotechnology companies are projected to witness the fastest growth with 5.97% CAGR during the forecast period 2026–2035.

By Product, reagents & kits dominated, while software & services grows fastest.

Reagents & kits, with a 63.00% share in 2025, hold the highest revenue owing to recurring use in routine diagnostic testing, disease screening, and bulk laboratory procedures. Global expansion in infectious diseases testing, Oncology Biomarker Detection, endocrine testing, and cardiac marker testing has led to increased reagents consumption across the world. In March 2026, Abbott introduced multiple new immunoassay assays to enhance the diagnostic menu on automated Alinity immunoassay systems that also support endocrine and infectious disease diagnostic needs thereby enabling enhanced laboratory testing capabilities.

Software & services segment to be expected at highest CAGR of 7.46% in the 2026-2035 forecast period. The segment is anticipated to witness swift growth due to growing adoption of cloud LIMS, growing acceptance of lab automation, AI in workflow automation, preventive maintenance features, real-time diagnostics services, and interconnected digital networks. Growing focus of Healthcare firms in enhancing the performance of integrated systems has bolstered adoption of digital tools for compliance, automation, QA, and reporting. In 2025, Roche Diagnostics bolstered digitalization trend through expanding cloud- capabilities in its laboratory management to establish connectivity within integrated Diagnostics.

By Technology, chemiluminescence immunoassay dominated, while fluorescence immunoassay grows fastest.

Chemiluminescence immunoassay (CLIA) accounted for 34.00% of the immunoassay market in 2025. It benefited from higher analytical sensitivity, higher sensitivity of detections, broader clinical application scope, higher throughput, quick report turnaround times, and ease of automation. CLIA systems are now commonly favored over immunoassay systems at clinical settings. Higher detection sensitivities, the capacity for extensive test volumes, better specificity and diagnostic sensitivity, and versatility in detecting various diseases-such as infectious disorders, oncological illnesses, endocrine problems, infertility tests, and cardio biomarker testing-all contribute to the use of these systems. In 2025, Siemens Healthineers improved its Atellica diagnosis portfolio and the availability of various chemiluminescence tests to reach larger clinics.

Fluorescence immunoassay is expected to grow at the quickest CAGR of 6.21% over the forecast period. Growing clinical requirements in the demand for rapid POC testing equipment, for centralized medical facilities as well as private health delivery systems and for better recognition of sensitive biomarker are pushing fluorescence assays. Improvements have also been noticed in developing compact fluorescent tests with greater sensitivity of detecting multiple biological factors in emergency medical care. A few diagnosis products launched include portable fluorescence assays for private delivery of facilities in 2026.

By Application, infectious diseases dominated, while oncology grows fastest.

The infectious disease, had 28.00% share of Immunoassay market in 2025 since there are continuous increase in demand for rapid detection of viral infections, bacterial infections, and parasitic infections from the different part of the world. Immunoassay systems are crucial during hepatitis, HIV, Influenza, respiratory, sexually transmitted and newly emerged infection screening in hospitals, public health laboratories. Continuously supported by government surveillance plan, increasing preparedness of laboratories and investments being made in infectious disease diagnostics the infectious disease segment remains to have consistent growth and hold over largest market share segment. The public health laboratories continued to increase capacity of automated immunoassay testing in 2025 in order to enhance ability to perform infectious disease surveillance, emerging pathogen detection and preparedness.

The oncology segment will experience the fastest growth rate CAGR)of 6.90% in forecast period. Higher incidences rate across the globe and use of tumor markers, precision oncology, companion diagnostics and personalized therapeutics drives immunoassay application in cancer testing procedures. Emerging research for new cancer biomarkers and integration of molecular diagnostics coupled with investment in targeted therapy from pharmaceutical continues to increase the clinical importance of immunoassay system in cancer screening and treatment. The immunoassay based cancer biomarker menu that support precision medicine and personalized treatment is increase over the hospital laboratories in 2026.

Regional Analysis:

North America Immunoassay Market Insights

The NA region led the global Immunoassay Market in terms of revenue share in 2025 with a dominance of 38.00%, owing to its well-established infrastructure for healthcare, vast implementation of automated clinical diagnostics, a prominent existence of the leading IVD manufacturers and high test usage across infectious diseases, oncology, endocrinology, cardiology and women’s health segment, which uphold to be a primary demand of the advanced immunoassay systems in the clinical settings of hospitals and reference laboratories.

The ongoing investment in lab automation, integrated diagnostics, AI-driven lab workflow optimization, precision medicine and the presence of robust reimbursement policies, favorable regulatory environment and the escalating growth in the expenditure on health provide strength and long-term leadership position to NA. Beckman Coulter Diagnostics added more value to the laboratory automation capabilities across its Immunoassay diagnostic platform- DxI in January 2026 with enhanced automation features aimed to enhance lab productivity and testing efficiencies.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe Immunoassay Market Insights      

Europe remains one of the largest regional markets for immunoassay supported by well-developed healthcare infrastructure, vast public screening programs and widespread adoption of high-throughput diagnostic technologies. Germany, France, UK, Italy, and Spain continue increasing investment in laboratory renovation, disease surveillance, cancer diagnostics, and biomarker based clinical decision-making. Stringent regulatory landscape, widespread implementation of lab quality standards and greater reliance on automated chemiluminescence and fluorescence immunoassay platforms are supporting adoption in the region.

Rise in demand in personalized medicine, early disease detection and companion diagnostics, driving clinical laboratories both in public and private space to bolster advanced immunodiagnostic capabilities. In 2025 some European health systems increased investment on lab automation and inclusion of digital pathology with the aim to consolidate diagnostic efficiencies and facilitate accessibility to precision diagnostic services.

Asia Pacific Immunoassay Market Insights

Asia Pacific Immunoassay Market is anticipated to grow at fastest CAGR of 7.03% during forecast period from 2026 to 2035. Growing healthcare infrastructure in the region, increasing diagnostic awareness, expanding universal healthcare schemes, and rising healthcare investments in China, India, Japan, South Korea, and Southeast Asia is exponentially growing demand for immunoassay technologies. Increasing prevalence of infectious diseases, chronic disease conditions, and cancer across the region has led to increased number of laboratory testing.

Both private and government healthcare owners are continuously investing in hospital modernizations, advanced automated diagnostic laboratories, improving local manufacturing capabilities, digital healthcare infrastructure, and operational efficiencies across the healthcare system in the countries, creating immense opportunities for the diagnostic market players irrespective of their global presence or regionally work for the forecast period. During 2026, several diagnostic manufacturers increased localized manufacturing and distribution alliances region wide to improve supply chains for immunoassay analyzers and diagnostic reagent portfolios in the Asia Pacific.

Middle East & Africa and Latin America Immunoassay Market Insights

The Middle East & Africa immunoassay market is set to witness a steady growth on back of advancements in healthcare infrastructure, increasing government spending on clinical laboratory facilities, and the rising number of Automated Diagnostic Systems being adopted across UAE, Saudi Arabia, South Africa & other key emerging healthcare markets. During 2025 some of the gulf countries expanded their investments in their National Diagnostic lab’s up-gradations by up scaling the adoption of automated diagnostic instruments for infectious disease testing & chronic diseases testing facilities.

Latin America market is expected to be steadily growing due to increasing healthcare spending, easy access of healthcare facilities & increasing awareness about disease diagnosis across Brazil, Mexico, Argentina, Chile etc. Factors supporting the increase of Immunoassay market in this region are increased spending on lab automation, Public healthcare checks with government focus on chronic conditions & Oncology diagnostic tests. Global diagnostics giants have strengthened their distribution networks in this region along with tying up with local stakeholders of health industry to make their Diagnostics better accessible & affordable to improve efficiency in lab processes.

Market Dynamics:                                                               

Growth Drivers: Rising demand for early disease detection and high-throughput diagnostic testing.

Proliferation of infectious diseases, cancer, cardiovascular disorders, endocrine diseases, and autoimmune diseases are expected to enhance the demand for rapid, sensitive diagnostic tools worldwide. Immunoassays are a vital part of modern clinical diagnostics owing to their desirable analytical sensitivity and specificity, automation, and less turnaround time. Artificial intelligence-enabled workflow management is anticipated to propel the immunoassay market throughout the forecast period. In March 2026 Abbott added the recently cleared diagnostic assay for infectious diseases and endocrine testing to its Alinity immunoassay testing menu, enhancing laboratory efficiency and expanding clinical testing potential.

Restraints: Investment, capital, lab costs are the constraints.

Despite the growth in sustained the lab automation equipment, digital health IT, high-performance equipment with high throughput. The lack of financial capital especially for the labs situated in smaller hospitals as well as diagnostic centers in the 3rd world countries will be a major barrier since most use the dated diagnostic equipment, equipment in lower end and thus delaying the adoption for higher quality automated diagnostics equipment and instruments for diagnostics in lab. In 2025 many diagnostic companies has adopted better options for the usage of such systems like leasing and other lab servicing systems in order to make accessible those machines and equipment’s.

Opportunities: Wider penetration in sustainable infrastructure and advanced manufacturing.

The broad-based proliferation of renewable energy sector- based ventures, fabrication of semiconductor manufacturing plants, EV manufacturing, modern architecture infrastructure provides tremendous scope for fluoropolymer coating manufactures in the future. The preference of materials that have increased life span, reduced maintenance and better resistance properties are driving the use of modern fluoropolymer technologies for different emerging applications.

The consistent effort of the manufactures towards development of low-VOC formulation, powder coatings systems and novel fluoropolymer chemistries help meet higher environmental compliances along with augmented coating performances. An intensified development of smart manufacturing facilities, automated industrial facilities and sustainable infrastructure projects is predicted to open lucrative market prospects over next ten years. In 2025, Arkema continued to advance its PVDF advanced materials solutions for sustainability, construction, clean energy infrastructure and various futuristic industrial applications.

Recent Developments:

• 2026: Abbott introduced additional immunoassay assays for its Alinity diagnostic platform, expanding testing capabilities across infectious diseases, endocrinology, and cardiac biomarkers while improving laboratory workflow efficiency.

• 2026: Roche Diagnostics strengthened its integrated diagnostics portfolio through enhanced digital laboratory connectivity and workflow automation supporting high-volume immunoassay laboratories.

• 2025: Siemens Healthineers expanded its Atellica immunoassay testing portfolio with additional automated assays designed to improve diagnostic accuracy and laboratory productivity across multiple clinical specialties.

• 2025: Beckman Coulter Diagnostics introduced workflow enhancements and expanded assay availability for its DxI immunoassay systems, supporting higher throughput and improved laboratory operational efficiency.

Immunoassay Market Key Players are:                       

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd

• Siemens Healthineers AG

• Danaher Corporation

• Thermo Fisher Scientific Inc.

• bioMérieux SA

• Bio-Rad Laboratories, Inc.

• QuidelOrtho Corporation

• Sysmex Corporation

• DiaSorin S.p.A.

• Agilent Technologies, Inc.

• Merck KGaA

• Revvity, Inc.

• Becton, Dickinson and Company

• Randox Laboratories Ltd.

• Trinity Biotech plc

• EKF Diagnostics Holdings plc

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

• Werfen S.A.

• Tosoh Corporation

Immunoassay Market Report Scope: